226 related articles for article (PubMed ID: 35581240)
1. Nuclear RNA transcript levels modulate nucleocytoplasmic distribution of ALS/FTD-associated protein FUS.
Tsai YL; Mu YC; Manley JL
Sci Rep; 2022 May; 12(1):8180. PubMed ID: 35581240
[TBL] [Abstract][Full Text] [Related]
2. Widespread FUS mislocalization is a molecular hallmark of amyotrophic lateral sclerosis.
Tyzack GE; Luisier R; Taha DM; Neeves J; Modic M; Mitchell JS; Meyer I; Greensmith L; Newcombe J; Ule J; Luscombe NM; Patani R
Brain; 2019 Sep; 142(9):2572-2580. PubMed ID: 31368485
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of FUS-associated ALS and FTD: insights from rodent models.
Nolan M; Talbot K; Ansorge O
Acta Neuropathol Commun; 2016 Sep; 4(1):99. PubMed ID: 27600654
[TBL] [Abstract][Full Text] [Related]
4. Nuclear transport dysfunction: a common theme in amyotrophic lateral sclerosis and frontotemporal dementia.
Jovičić A; Paul JW; Gitler AD
J Neurochem; 2016 Aug; 138 Suppl 1():134-44. PubMed ID: 27087014
[TBL] [Abstract][Full Text] [Related]
5. Dendritic Homeostasis Disruption in a Novel Frontotemporal Dementia Mouse Model Expressing Cytoplasmic Fused in Sarcoma.
Shiihashi G; Ito D; Arai I; Kobayashi Y; Hayashi K; Otsuka S; Nakajima K; Yuzaki M; Itohara S; Suzuki N
EBioMedicine; 2017 Oct; 24():102-115. PubMed ID: 28928015
[TBL] [Abstract][Full Text] [Related]
6. TDP-43 and FUS en route from the nucleus to the cytoplasm.
Ederle H; Dormann D
FEBS Lett; 2017 Jun; 591(11):1489-1507. PubMed ID: 28380257
[TBL] [Abstract][Full Text] [Related]
7. Rapid in vitro quantification of TDP-43 and FUS mislocalisation for screening of gene variants implicated in frontotemporal dementia and amyotrophic lateral sclerosis.
Oyston LJ; Ubiparipovic S; Fitzpatrick L; Hallupp M; Boccanfuso LM; Kwok JB; Dobson-Stone C
Sci Rep; 2021 Jul; 11(1):14881. PubMed ID: 34290285
[TBL] [Abstract][Full Text] [Related]
8. Expression of Fused in sarcoma mutations in mice recapitulates the neuropathology of FUS proteinopathies and provides insight into disease pathogenesis.
Verbeeck C; Deng Q; Dejesus-Hernandez M; Taylor G; Ceballos-Diaz C; Kocerha J; Golde T; Das P; Rademakers R; Dickson DW; Kukar T
Mol Neurodegener; 2012 Oct; 7():53. PubMed ID: 23046583
[TBL] [Abstract][Full Text] [Related]
9. Extensive splicing changes in an ALS/FTD transgenic mouse model overexpressing cytoplasmic fused in sarcoma.
Ito D; Taguchi R; Deguchi M; Ogasawara H; Inoue E
Sci Rep; 2020 Mar; 10(1):4857. PubMed ID: 32184412
[TBL] [Abstract][Full Text] [Related]
10. Neuronal dysfunction caused by FUSR521G promotes ALS-associated phenotypes that are attenuated by NF-κB inhibition.
Pelaez MC; Desmeules A; Gelon PA; Glasson B; Marcadet L; Rodgers A; Phaneuf D; Pozzi S; Dutchak PA; Julien JP; Sephton CF
Acta Neuropathol Commun; 2023 Nov; 11(1):182. PubMed ID: 37974279
[TBL] [Abstract][Full Text] [Related]
11. Protein disulphide isomerase (PDI) is protective against amyotrophic lateral sclerosis (ALS)-related mutant Fused in Sarcoma (FUS) in in vitro models.
Parakh S; Perri ER; Vidal M; Sultana J; Shadfar S; Mehta P; Konopka A; Thomas CJ; Spencer DM; Atkin JD
Sci Rep; 2021 Sep; 11(1):17557. PubMed ID: 34475430
[TBL] [Abstract][Full Text] [Related]
12. ALS/FTD-Linked Mutation in FUS Suppresses Intra-axonal Protein Synthesis and Drives Disease Without Nuclear Loss-of-Function of FUS.
López-Erauskin J; Tadokoro T; Baughn MW; Myers B; McAlonis-Downes M; Chillon-Marinas C; Asiaban JN; Artates J; Bui AT; Vetto AP; Lee SK; Le AV; Sun Y; Jambeau M; Boubaker J; Swing D; Qiu J; Hicks GG; Ouyang Z; Fu XD; Tessarollo L; Ling SC; Parone PA; Shaw CE; Marsala M; Lagier-Tourenne C; Cleveland DW; Da Cruz S
Neuron; 2018 Nov; 100(4):816-830.e7. PubMed ID: 30344044
[TBL] [Abstract][Full Text] [Related]
13. Interactions between FUS and the C-terminal Domain of Nup62 are Sufficient for their Co-phase Separation into Amorphous Assemblies.
Kumar MS; Stallworth KM; Murthy AC; Lim SM; Li N; Jain A; Munro JB; Fawzi NL; Lagier-Tourenne C; Bosco DA
J Mol Biol; 2023 Mar; 435(6):167972. PubMed ID: 36690069
[TBL] [Abstract][Full Text] [Related]
14. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1.
Ederle H; Funk C; Abou-Ajram C; Hutten S; Funk EBE; Kehlenbach RH; Bailer SM; Dormann D
Sci Rep; 2018 May; 8(1):7084. PubMed ID: 29728564
[TBL] [Abstract][Full Text] [Related]
15. Loss of Dynamic RNA Interaction and Aberrant Phase Separation Induced by Two Distinct Types of ALS/FTD-Linked FUS Mutations.
Niaki AG; Sarkar J; Cai X; Rhine K; Vidaurre V; Guy B; Hurst M; Lee JC; Koh HR; Guo L; Fare CM; Shorter J; Myong S
Mol Cell; 2020 Jan; 77(1):82-94.e4. PubMed ID: 31630970
[TBL] [Abstract][Full Text] [Related]
16. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations.
Daigle JG; Lanson NA; Smith RB; Casci I; Maltare A; Monaghan J; Nichols CD; Kryndushkin D; Shewmaker F; Pandey UB
Hum Mol Genet; 2013 Mar; 22(6):1193-205. PubMed ID: 23257289
[TBL] [Abstract][Full Text] [Related]
17. TDP-43 and FUS in amyotrophic lateral sclerosis and frontotemporal dementia.
Mackenzie IR; Rademakers R; Neumann M
Lancet Neurol; 2010 Oct; 9(10):995-1007. PubMed ID: 20864052
[TBL] [Abstract][Full Text] [Related]
18. Conjoint pathologic cascades mediated by ALS/FTLD-U linked RNA-binding proteins TDP-43 and FUS.
Ito D; Suzuki N
Neurology; 2011 Oct; 77(17):1636-43. PubMed ID: 21956718
[TBL] [Abstract][Full Text] [Related]
19. Lysine acetylation regulates the RNA binding, subcellular localization and inclusion formation of FUS.
Arenas A; Chen J; Kuang L; Barnett KR; Kasarskis EJ; Gal J; Zhu H
Hum Mol Genet; 2020 Sep; 29(16):2684-2697. PubMed ID: 32691043
[TBL] [Abstract][Full Text] [Related]
20. Nuclear-import receptors as gatekeepers of pathological phase transitions in ALS/FTD.
Khalil B; Linsenmeier M; Smith CL; Shorter J; Rossoll W
Mol Neurodegener; 2024 Jan; 19(1):8. PubMed ID: 38254150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
